selected publications
- Multi-omic analysis reveals a key BCAT1 role in mTOR activation by B-cell receptor and TLR9. The Journal of clinical investigation. 2025 Academic Article GET IT
-
A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma.
Journal of medicinal chemistry.
2024
Academic Article
GET IT
Times cited: 7 -
Multilayered Immunity by Tissue-Resident Lymphocytes in Cancer.
Annual review of immunology.
2024
Review
GET IT
Times cited: 2 - Multi-omic Analysis of Human B-cell Activation Reveals a Key Lysosomal BCAT1 Role in mTOR Hyperactivation by B-cell receptor and TLR9. 2024 GET IT
-
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity.
Haematologica.
2023
Academic Article
GET IT
Times cited: 23 -
Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival.
Blood cancer discovery.
2021
Academic Article
GET IT
Times cited: 20 -
Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia.
Blood cancer discovery.
2021
Comment
GET IT
Times cited: 6 -
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence.
Cancer discovery.
2021
Academic Article
GET IT
Times cited: 175 -
An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?.
Cancer discovery.
2019
Comment
GET IT
Times cited: 2 -
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.
Cancer cell.
2019
Academic Article
GET IT
Times cited: 95